CoMind DuoSense: Developing a new standard-of-care for monitoring the injured brain

今天，即使在世界上最先进、资金最充足的医院里，医生也无法直接测量人体最脆弱、最重要的器官：大脑。可用的临床工具仅限于那些高度侵入性（例如在头部钻孔），高度不准确（例如脑氧饱和度测定法）或两者兼而有之的工具。在CoMind，我们开发了一种新型的大脑监测技术。我们的技术已经处于医疗设备开发过程中，我们的第一款产品的临床试验将于2023年底开始。在这个项目中，我们将把我们世界领先的技术带到一个全新的方向，并为CoMind的技术已经可以提供的关键临床信号增加一个新的维度。通过重新配置我们的技术并进行有针对性的临床试验，该项目将使我们的技术能够准确和绝对地测量最关键的神经参数之一：脑血流量。脑血流量（或脑血流量，CBF）对大脑健康至关重要：血流量过少，大脑就会缺氧，血流量过多，大脑肿胀和中风的风险就会增加。在重症监护和麻醉期间，管理患者的脑血流是患者预后的关键，但目前还没有技术允许医生在床边连续测量脑血流。该项目将以CoMind最近的创新为基础，创造一种新的原型技术。我们将在实验室的健康志愿者身上测试和验证这个原型，然后将这个原型作为目标临床试验的一部分部署到临床环境中。一旦完成，我们将把在这个项目中取得的进展整合到我们现有的产品开发途径中，以实现一个全新的多参数神经监测设备，能够测量几个关键的神经生理信号，包括绝对脑血流量。从重症监护病房到手术室，该设备将对众多患者群体产生直接而深远的影响。该项目的成功将使CoMind能够确保更多的患者和医生尽快获得这项技术，从而改善患者的治疗结果、生活质量和我们国家医疗保健系统的功效。

Today, even in the most sophisticated and well-funded hospitals in the world, doctors have no direct measures of the most vulnerable, vital organ in the body: the brain. The clinical tools available are limited to those that are either highly invasive (e.g. drilling a hole in the head), highly inaccurate (e.g. cerebral oximetry methods), or both.At CoMind, we have developed a novel form of brain monitoring technology. Our technology is already in the medical device development process, with clinical trials of our first product due to begin in late 2023\.In this project, we will take our world-leading technology in a whole new direction, and add a new dimension to the critical clinical signals that CoMind's technology can already provide. By re-configuring our technology and undertaking a targeted clinical trial, this project will enable our technology to measure accurate and **absolute** measures of one of the most critical neurological parameters of all: brain blood flow. Brain blood flow (or **Cerebral Blood Flow**, CBF) is critical to brain health: too little flow and the brain suffers from a lack of oxygen, too much and the brain is at increased risk of brain swelling and stroke. Managing a patient's CBF is key to patient outcomes in intensive care and during anaesthesia, but there is currently no technology that permits doctors to measure CBF continuously at the bedside.This project will build on the recent innovations made at CoMind to create a new prototype technology. We will test and validate this prototype in healthy volunteers in the laboratory and then deploy this prototype into the clinical environment as part of a targeted clinical trial. Once complete, we will integrate the advances made in this project into our existing product development pathway to achieve a completely novel multi-parameter neuromonitoring device capable of measuring several critical neurophysiological signals including absolute Cerebral Blood Flow. This device will have an immediate and far-reaching impact across numerous patient groups, from the intensive care unit, to the operating theatre. The success of this project will allow CoMind to ensure more patients and doctors have access to this technology as soon as possible, improving patient outcomes, quality-of-life, and the efficacy of our National Healthcare System.